<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-23410" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Impetigo</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Nardi</surname>
            <given-names>Naomi M.</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Schaefer</surname>
            <given-names>Timothy J.</given-names>
          </name>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Naomi Nardi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Timothy Schaefer declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>31</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-23410.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Impetigo is a common infection of the superficial layers of the epidermis that is highly contagious and most commonly caused by gram-positive bacteria. It most commonly presents as erythematous plaques with a yellow crust and may be itchy or painful. The lesions are highly contagious and spread easily. Diagnosis is typically based on the symptoms and clinical manifestations alone. Treatment involves topical and oral antibiotics and symptomatic care. This activity reviews the cause, pathophysiology and presentation of impetigo and highlights the role of the interprofessional team in its management.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Recall the cause of impetigo.</p></list-item><list-item><p>Describe the presentation of impetigo.</p></list-item><list-item><p>Summarize the treatment of impetigo.</p></list-item><list-item><p>Review the importance of improving care coordination among interprofessional team members to improve outcomes for patients affected by impetigo.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=23410&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=23410">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-23410.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>&#x000a0;Impetigo is a common infection of the superficial layers of the epidermis that is highly contagious and most commonly caused by gram-positive bacteria. It most commonly presents as erythematous plaques with a yellow crust and may be itchy or painful.&#x000a0; The lesions are highly contagious and spread easily.</p>
        <p>Impetigo is a disease of children who reside in hot humid climates. The infection may be bullous or nonbullous. The infection typically affects the face but can also occur in any other part of the body that has an abrasion, laceration, insect bite or other trauma.</p>
        <p>Diagnosis is typically based on the symptoms and clinical manifestations alone. Treatment involves topical and oral antibiotics and symptomatic care.<xref ref-type="bibr" rid="article-23410.r1">[1]</xref><xref ref-type="bibr" rid="article-23410.r2">[2]</xref><xref ref-type="bibr" rid="article-23410.r3">[3]</xref></p>
      </sec>
      <sec id="article-23410.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Impetigo accounts for approximately 10% of skin complaints in the pediatric population. When considering all age ranges, the incidence is the same in males and females.&#x000a0; In adults, men are more commonly affected.&#x000a0; It is most prevalent in children aged 2-5 years old but can occur at any age. The peak incidence is during summer and fall. Bullous impetigo is more common in infants.&#x000a0; Children younger than two account for 90% of cases of bullous impetigo.<xref ref-type="bibr" rid="article-23410.r4">[4]</xref><xref ref-type="bibr" rid="article-23410.r5">[5]</xref><xref ref-type="bibr" rid="article-23410.r6">[6]</xref><xref ref-type="bibr" rid="article-23410.r7">[7]</xref></p>
      </sec>
      <sec id="article-23410.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Nonbullous impetigo is most commonly caused by <italic toggle="yes">S aureus</italic> which is responsible for 80% of cases. Group A beta-hemolytic <italic toggle="yes">Strep</italic> (GABHS) accounts for 10% of cases and the causative agent is a combination of <italic toggle="yes">S. aureus</italic> and GABHS 10% of the time. Methicillin-resistant <italic toggle="yes">S aureus</italic> (MRSA) has become more prevalent, especially in hospitalized patients. Today, community-acquired MRSA is rapidly increasing. The condition is more common in populations living in close quarters, daycare centers and prisons.</p>
        <p>Bullous impetigo is caused almost exclusively by <italic toggle="yes">S aureus</italic>. Sometimes a deep ulcerated infection may occur known as ecthyma, which is a complication of bullous impetigo.</p>
      </sec>
      <sec id="article-23410.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Impetigo can be classified as either primary or secondary.&#x000a0; Primary impetigo involves previously normal skin affected by direct bacterial invasion.&#x000a0; Secondary impetigo involves infection forming at a previous skin wound site.</p>
        <p>Any disturbance of the skin barrier leads to access to fibronectin receptors by GABHS and <italic toggle="yes">S aureus</italic> which require fibronectin for colonization. Trauma, cuts, insect bites, surgery, atopic dermatitis, burns, and varicella are common mechanisms of skin breakdown. Once a lesion is present, self-inoculation to other sites is very common. Malnutrition, immunosuppression, daycare attendance, overcrowding, diabetes, and poor hygiene make one more susceptible to impetigo.</p>
        <p>Triggers that breakdown skin and increase susceptibility to impetigo include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Varicella</p>
          </list-item>
          <list-item>
            <p>Herpes</p>
          </list-item>
          <list-item>
            <p>Scratching</p>
          </list-item>
          <list-item>
            <p>Lice</p>
          </list-item>
          <list-item>
            <p>Burns</p>
          </list-item>
          <list-item>
            <p>Trauma</p>
          </list-item>
          <list-item>
            <p>Insect bites</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-23410.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Nonbullous impetigo often starts as a vesicle or a pustule. Multiple vesicles often coalesce and rupture after which the purulent exudate forms the characteristic honey-colored crust. An erythematous base is also present.&#x000a0; There are often multiple lesions on the face and extremities, especially in areas in which disruption of the skin barrier has occurred.&#x000a0; The rapid spread and satellite lesion formation follow self-inoculation, often in areas with no apparent break in the skin barrier. Mild regional lymphadenopathy is a common associated finding. Systemic symptoms such as fever are typically absent in nonbullous impetigo.</p>
        <p>Bullous impetigo begins with small vesicles that become flaccid bullae. The exfoliative toxin A produced by S. aureus causes loss of cell adhesion in the superficial epidermis. The bullae contain a clear or yellow fluid which eventually progresses to become purulent or dark. Surrounding erythema and edema are typically absent.&#x000a0; Once the bullae rupture, an erythematous base with a rim of scale remains. Bullous impetigo does not form a honey-colored crust. Lesions most commonly form in the intertriginous regions and on the trunk and, unlike nonbullous impetigo, may occur in the buccal membranes.&#x000a0; There are typically fewer lesions present than in non-bullous impetigo. &#x000a0;Regional lymphadenopathy is absent. Systemic symptoms, such as fever, are more common than in nonbullous impetigo.</p>
        <p>Ecthyma is a deep tissue form of impetigo. Ulcerative lesions penetrate through the epidermis and deep into the dermis.&#x000a0; These ulcers appear as &#x0201c;punched out&#x0201d; lesions with violaceous margins. The crusts can be honey-colored or brown-black. The lesions may be purulent.</p>
      </sec>
      <sec id="article-23410.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>History and physical exam are essential to the diagnosis of impetigo.&#x000a0; Bacterial cultures can be used for confirmation of diagnosis and should be obtained if methicillin-resistant <italic toggle="yes">staph aureus</italic> (MRSA) is suspected or if an impetigo outbreak is present.&#x000a0; A skin biopsy may be considered if the case is refractory.</p>
        <p>The anti-streptolysin O (ASO) response is weak from impetigo alone. Therefore, serologic testing for streptococcal antibodies is not indicated for the diagnosis of impetigo. However, it may be useful if post-streptococcal glomerulonephritis is suspected in a patient with a recent impetigo outbreak.</p>
        <p>Human immunodeficiency virus (HIV) testing should be considered when a previously healthy adult develops bullous impetigo.</p>
      </sec>
      <sec id="article-23410.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Topical antibiotics alone or in conjunction with systemic antibiotics are used to treat impetigo. Antibiotic coverage should cover both <italic toggle="yes">S aureus</italic> and <italic toggle="yes">S pyogenes </italic>(i.e. GABHS). While untreated impetigo is often self-limiting, antibiotics decrease the duration of illness and spread of lesions. In addition, antibiotic treatment decreases the chances of complications involving kidneys, joints, bones, and lungs, as well as acute rheumatic fever.<xref ref-type="bibr" rid="article-23410.r8">[8]</xref><xref ref-type="bibr" rid="article-23410.r9">[9]</xref><xref ref-type="bibr" rid="article-23410.r10">[10]</xref></p>
        <p>For localized, uncomplicated, non-bullous impetigo, topical therapy alone is the treatment of choice.&#x000a0; The crust should be removed with soap and water before the application of topical antibiotic therapy. Mupirocin, retapamulin, and fusidic acid are the treatments of choice.</p>
        <p>Systemic antibiotics should be prescribed for all cases of bullous impetigo and cases of non-bullous impetigo with more than five lesions, deep tissue involvement, systemic signs of infection, lymphadenopathy or lesions in the oral cavity. Beta-lactamase-resistant antibiotics such as cephalosporins, amoxicillin-clavulanate, dicloxacillin are the treatment of choice. Cephalexin is commonly used. If culture confirms an infection solely caused by streptococci, oral penicillin is the preferred therapy.</p>
        <p>In areas of high prevalence of MRSA&#x000a0; or if cultures are positive for MRSA, clindamycin or doxycycline are the preferred treatments. Trimethoprim-sulfamethoxazole is effective against MRSA, but should only be used if group A streptococci are not the causative agent, or in addition to an anti-streptococcal antibiotic.</p>
        <p>Children with impetigo should maintain good personal hygiene and avoid other children during the active outbreak. It is important to wash hands, linens, clothes and affected areas that may have come into contact with infected fluids. Sores can be covered with a bandage to help prevent spread by contact. If impetigo is recurrent, evaluation for carriage of the causative bacteria should be performed.&#x000a0; The nose is a common reservoir and carriers can be treated with&#x000a0;mupirocin (Bactroban Nasal)&#x000a0;applied in the nostrils.</p>
      </sec>
      <sec id="article-23410.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <list list-type="bullet">
          <list-item>
            <p>Atopic dermatitis</p>
          </list-item>
          <list-item>
            <p>Scabies</p>
          </list-item>
          <list-item>
            <p>Contact dermatitis</p>
          </list-item>
          <list-item>
            <p>Herpes simplex</p>
          </list-item>
          <list-item>
            <p>Candidiasis</p>
          </list-item>
          <list-item>
            <p>Varicella zoster</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-23410.s10" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Without treatment, the infection heals in 14-21 days. About 20% of cases resolve spontaneously. Scarring is rare but some patients may develop pigmentation changes. Some patients may develop ecthyma. With treatment, cure occurs within 10 days. Neonates may develop meningitis. A rare complication is acute post streptococcal glomerulonephritis, whic occurs 2-3 weeks after the skin infection.</p>
      </sec>
      <sec id="article-23410.s11" sec-type="Complications">
        <title>Complications</title>
        <p>While most patients do improve with therapy, a few patients may develop renal failure. This is more likely if the infection is due to streptococcus. The renal dysfunction appears 7-14 days after the infection. The transient hematuria and proteinuria may last a few weeks or months. Other complications include septic arthritis, scarlet fever, sepsis, and staphylococcal scalded skin syndrome.</p>
      </sec>
      <sec id="article-23410.s12" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>Approximately 5% of patients with impetigo will develop an associated glomerulonephritis.&#x000a0; There is inconclusive evidence about whether or not antibiotics help reduce the incidence of poststreptococcal glomerulonephritis.&#x000a0; Poststreptococcal glomerulonephritis typically occurs one to two weeks after a streptococcal infection. Patients may experience fever, hypertension, edema and hematuria.</p>
      </sec>
      <sec id="article-23410.s13" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Impetigo is usually&#x000a0;managed by an interprofessional team that&#x000a0;consists of a nurse practitioner, primary care provider, pediatrician, and a dermatologist.&#x000a0;Topical antibiotics alone or in conjunction with systemic antibiotics are used to treat impetigo. Antibiotic coverage should cover both&#x000a0;<italic toggle="yes">S aureus</italic>&#x000a0;and&#x000a0;<italic toggle="yes">S&#x000a0;pyogenes&#x000a0;</italic>(i.e. GABHS). While untreated impetigo is often self-limiting, antibiotics decrease the duration of illness and spread of lesions. In addition, antibiotic treatment decreases the chances of complications involving kidneys, joints, bones, and lungs, as well as acute rheumatic fever.</p>
        <p>The infectious disease should educate the patient to refrain from touching the skin lesions and the importance of handwashing. Because the infection is contagious, the school nurse should recommend that the child not return to daycare os school for at least 24-48 hours after starting antibiotic therapy.</p>
        <p>In areas of a high prevalence of MRSA&#x000a0; or if cultures are positive for MRSA, clindamycin or doxycycline are the preferred treatments. Trimethoprim-sulfamethoxazole is effective against MRSA, but should only be used if group A streptococci are not the causative agent, or in addition to an anti-streptococcal antibiotic.</p>
        <p>Clinicians should educate the caregivers that children with impetigo should maintain good personal hygiene and avoid other children during the active outbreak. It is important to wash hands, linens, clothes and affected areas that may have come into contact with infected fluids. Sores can be covered with a bandage to help prevent spread by contact. If impetigo is recurrent, evaluation for the carriage of the causative bacteria should be performed.&#x000a0; The nose is a common reservoir and carriers can be treated with&#x000a0;mupirocin (Bactroban Nasal)&#x000a0;applied in the nostrils.</p>
        <p>
<bold>Outcomes</bold>
</p>
        <p>Children with severe impetigo should be followed because a small number may develop glomerulonephritis. The outcomes in most other cases are excellent. <xref ref-type="bibr" rid="article-23410.r11">[11]</xref><xref ref-type="bibr" rid="article-23410.r12">[12]</xref>(Level V)</p>
      </sec>
      <sec id="article-23410.s14">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=23410&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=23410">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/child-health/impetigo/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=23410">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/23410/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=23410">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-23410.s15">
        <fig id="article-23410.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Impetigo, Skin Infection <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://dermnetnz.org/images">DermNet New Zealand</ext-link></p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="impetigo" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-23410.s16">
        <fig id="article-23410.image.f2" position="float" orientation="portrait">
          <caption>
            <p>Impetigo in a child Image Courtesy S Bhimji MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="impetigo" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-23410.s17">
        <title>References</title>
        <ref id="article-23410.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>May</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Tong</surname>
                <given-names>SYC</given-names>
              </name>
              <name>
                <surname>Steer</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Currie</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Andrews</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Carapetis</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Bowen</surname>
                <given-names>AC</given-names>
              </name>
            </person-group>
            <article-title>Treatment, prevention and public health management of impetigo, scabies, crusted scabies and fungal skin infections in endemic populations: a systematic review.</article-title>
            <source>Trop Med Int Health</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>24</volume>
            <issue>3</issue>
            <fpage>280</fpage>
            <page-range>280-293</page-range>
            <pub-id pub-id-type="pmid">30582783</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23410.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Leung</surname>
                <given-names>TN</given-names>
              </name>
              <name>
                <surname>Hon</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Leung</surname>
                <given-names>AK</given-names>
              </name>
            </person-group>
            <article-title>Group A Streptococcus disease in Hong Kong children: an overview.</article-title>
            <source>Hong Kong Med J</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>24</volume>
            <issue>6</issue>
            <fpage>593</fpage>
            <page-range>593-601</page-range>
            <pub-id pub-id-type="pmid">30416105</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23410.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Clebak</surname>
                <given-names>KT</given-names>
              </name>
              <name>
                <surname>Malone</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Skin Infections.</article-title>
            <source>Prim Care</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>45</volume>
            <issue>3</issue>
            <fpage>433</fpage>
            <page-range>433-454</page-range>
            <pub-id pub-id-type="pmid">30115333</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23410.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Breyre</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Frazee</surname>
                <given-names>BW</given-names>
              </name>
            </person-group>
            <article-title>Skin and Soft Tissue Infections in the Emergency Department.</article-title>
            <source>Emerg Med Clin North Am</source>
            <year>2018</year>
            <month>Nov</month>
            <volume>36</volume>
            <issue>4</issue>
            <fpage>723</fpage>
            <page-range>723-750</page-range>
            <pub-id pub-id-type="pmid">30297001</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23410.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sahu</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Mishra</surname>
                <given-names>AK</given-names>
              </name>
            </person-group>
            <article-title>Ozenoxacin: A Novel Drug Discovery for the Treatment of Impetigo.</article-title>
            <source>Curr Drug Discov Technol</source>
            <year>2019</year>
            <volume>16</volume>
            <issue>3</issue>
            <fpage>259</fpage>
            <page-range>259-264</page-range>
            <pub-id pub-id-type="pmid">29732990</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23410.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Castro</surname>
                <given-names>MCR</given-names>
              </name>
              <name>
                <surname>Ramos-E-Silva</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Cutaneous infections in the mature patient.</article-title>
            <source>Clin Dermatol</source>
            <year>2018</year>
            <season>Mar-Apr</season>
            <volume>36</volume>
            <issue>2</issue>
            <fpage>188</fpage>
            <page-range>188-196</page-range>
            <pub-id pub-id-type="pmid">29566923</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23410.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dayrit</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Bintanjoyo</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Andersen</surname>
                <given-names>LK</given-names>
              </name>
              <name>
                <surname>Davis</surname>
                <given-names>MDP</given-names>
              </name>
            </person-group>
            <article-title>Impact of climate change on dermatological conditions related to flooding: update from the International Society of Dermatology Climate Change Committee.</article-title>
            <source>Int J Dermatol</source>
            <year>2018</year>
            <month>Aug</month>
            <volume>57</volume>
            <issue>8</issue>
            <fpage>901</fpage>
            <page-range>901-910</page-range>
            <pub-id pub-id-type="pmid">29377078</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23410.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Loadsman</surname>
                <given-names>MEN</given-names>
              </name>
              <name>
                <surname>Verheij</surname>
                <given-names>TJM</given-names>
              </name>
              <name>
                <surname>van der Velden</surname>
                <given-names>AW</given-names>
              </name>
            </person-group>
            <article-title>Impetigo incidence and treatment: a retrospective study of Dutch routine primary care data.</article-title>
            <source>Fam Pract</source>
            <year>2019</year>
            <month>Jul</month>
            <day>31</day>
            <volume>36</volume>
            <issue>4</issue>
            <fpage>410</fpage>
            <page-range>410-416</page-range>
            <pub-id pub-id-type="pmid">30346521</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23410.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Smith</surname>
                <given-names>DRM</given-names>
              </name>
              <name>
                <surname>Dolk</surname>
                <given-names>FCK</given-names>
              </name>
              <name>
                <surname>Pouwels</surname>
                <given-names>KB</given-names>
              </name>
              <name>
                <surname>Christie</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Robotham</surname>
                <given-names>JV</given-names>
              </name>
              <name>
                <surname>Smieszek</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Defining the appropriateness and inappropriateness of antibiotic prescribing in primary care.</article-title>
            <source>J Antimicrob Chemother</source>
            <year>2018</year>
            <month>Feb</month>
            <day>01</day>
            <volume>73</volume>
            <issue>suppl_2</issue>
            <fpage>ii11</fpage>
            <page-range>ii11-ii18</page-range>
            <pub-id pub-id-type="pmid">29490061</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23410.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rush</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Dinulos</surname>
                <given-names>JG</given-names>
              </name>
            </person-group>
            <article-title>Childhood skin and soft tissue infections: new discoveries and guidelines regarding the management of bacterial soft tissue infections, molluscum contagiosum, and warts.</article-title>
            <source>Curr Opin Pediatr</source>
            <year>2016</year>
            <month>Apr</month>
            <volume>28</volume>
            <issue>2</issue>
            <fpage>250</fpage>
            <page-range>250-7</page-range>
            <pub-id pub-id-type="pmid">26900921</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23410.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rosen</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Albareda</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Rosenberg</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Alonso</surname>
                <given-names>FG</given-names>
              </name>
              <name>
                <surname>Roth</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Zsolt</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Hebert</surname>
                <given-names>AA</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and Safety of Ozenoxacin Cream for Treatment of Adult and Pediatric Patients With Impetigo: A Randomized Clinical Trial.</article-title>
            <source>JAMA Dermatol</source>
            <year>2018</year>
            <month>Jul</month>
            <day>01</day>
            <volume>154</volume>
            <issue>7</issue>
            <fpage>806</fpage>
            <page-range>806-813</page-range>
            <pub-id pub-id-type="pmid">29898217</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23410.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nasr</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Fidler</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Valeri</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Cornell</surname>
                <given-names>LD</given-names>
              </name>
              <name>
                <surname>Sethi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Zoller</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Stokes</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Markowitz</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>D'Agati</surname>
                <given-names>VD</given-names>
              </name>
            </person-group>
            <article-title>Postinfectious glomerulonephritis in the elderly.</article-title>
            <source>J Am Soc Nephrol</source>
            <year>2011</year>
            <month>Jan</month>
            <volume>22</volume>
            <issue>1</issue>
            <fpage>187</fpage>
            <page-range>187-95</page-range>
            <pub-id pub-id-type="pmid">21051737</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
